AAS
PRTK

Annex Advisory Services’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Annex Advisory Services’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,700
Closed -$73K – 134
2019
Q1 		$73K Sell
13,700
-1,400
-9% -$9.04K 0.01% 130
2018
Q4 		$77K Buy
15,100
+2,000
+15% +$15.2K 0.01% 125
2018
Q3 		$127K Hold
13,100
– – 0.02% 129
2018
Q2 		$134K Buy
+13,100
New +$148K 0.02% 123

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Annex Advisory Services's PRTK Position: Q2 2019 in Review

Annex Advisory Services sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2019, closing a stake of 13,700 shares — an estimated $73K sold.

Annex Advisory Services first reported a position in PRTK in Q2 2018 and held it in 4 quarters. The position peaked at $134K in Q2 2018. 89 funds tracked by Wall St. Rank hold PRTK as of Q2 2019.

  • Annex Advisory Services reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Annex Advisory Services sold 13,700 Paratek Pharmaceuticals, Inc. shares in Q2 2019, an estimated $73K.
  • Annex Advisory Services first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 4 quarters.
  • Annex Advisory Services's Paratek Pharmaceuticals, Inc. position peaked at $134K in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2019.

Based on Annex Advisory Services's 13F filing for Q2 2019, filed 18 Jul 2019.